BR Biomedical Reports 2049-9434 2049-9442 D.A. Spandidos 10.3892/br.2017.897 BR-0-0-897 Articles Barley grass extract causes apoptosis of cancer cells by increasing intracellular reactive oxygen species production WooSang Mi 1 * KwonSang-Chul 2 * KoSeong Gyu 1 ChoSung-Gook 3 Department of Science in Korean Medicine, Graduate School of Kyung Hee University, Seoul 130-701, Republic of Korea Department of Food Technology, Korea National University of Transportation, Jeungpyeong, Chungbuk 368-701, Republic of Korea Department of Biotechnology, Korea National University of Transportation, Jeungpyeong, Chungbuk 368-701, Republic of Korea Correspondence to: Professor Sung-Gook Cho, Department of Biotechnology, Korea National University of Transportation, 61 University Road, Jeungpyeong, Chungbuk 368-701, Republic of Korea, E-mail: chosg@ut.ac.kr

Contributed equally

 06 2017 03 05 2017 6 6 681 685 11112016 10012017 Copyright © 2017, Spandidos Publications 2017

Cancer remains a leading cause of mortality worldwide, therefore food products are being investigated for potential prevention or treatment strategies. The ingredient, barley grass extract (Hordeum vulgare L.; Bex) is used to prevent or ameliorate various types of disease. In cancer, Bex has been revealed to inhibit tumor growth. However, its effect on cancer cells is yet to be clearly defined. In the present study, the effect of Bex on cancer cell growth was investigated. Bex inhibited the viabilities of breast and prostate cancer cells according to the results of MTT assays. Accordingly, Bex caused apoptosis, which was confirmed by Annexin V staining and western blot analysis for poly (ADP-ribose) polymerase and caspases. Furthermore, Bex increased the intracellular levels of reactive oxygen species (ROS), and N-acetyl-L-cystein blocked Bex-induced apoptosis. Therefore, the study demonstrated that Bex causes apoptosis of breast and prostate cancer cells by increasing intracellular ROS levels.

 barley grass extract cancer reactive oxygen species Introduction

Cancer is one of the leading causes of mortality worldwide (1,2). Despite numerous cancer studies and the development of various anti-cancer therapeutic agents, cancer remains dangerous. Anti-cancer therapeutic agents are chemically or biologically produced, and their effects are well defined (3–7). However, treatments continue to be associated with adverse effects and the majority of patients have an aversion to them (8).

Herbal products have long been used to prevent or treat diseases, including cancer (9–12). Furthermore, certain anti-cancer therapeutic agents that are chemically produced originate from herbal products and their chemical characteristics are modified (7,12–14). Typically, patients prefer to take herbal products (15–18); herbal products have historically been used as traditional medicines, such as traditional Chinese and Korean medicines, Kampo medicines and Ayurvedic medicine (13,14,19). Certain herbal products were demonstrated to treat cancer and/or reduce the side effects of cancer treatment (13,15–17,19–21). Therefore, herbal products are considered to be promising for cancer prevention and treatment.

Barley grass extract (Hordeum vulgare L.; Bex) has long been used as a food product. Its biological effects have also been addressed by various in vitro and in vivo studies, although evidence there is limited evidence of the efficacy of Bex against specific conditions (22). The effect of Bex on the immune system was revealed in in vitro and in vivo experimental sets (23–25). Accordingly, Bex inhibited atopic dermatitis in NC/Nga mice by altering the expression levels of cytokines (26). Similarly, Bex repressed lipopolysaccharide-induced inflammation (27). Furthermore, its effect in type 2 diabetes was revealed in a genetically engineered mouse model and patients (28,29). Therefore, the effects of Bex on particular diseases have been demonstrated at least in experimental systems. A previous study revealed that Bex caused apoptosis of leukemia and lymphoma cell lines (30); however, its effect in cancer remains unclear.

The present study examined the effect of Bex in different cancer cell lines, including breast cancer MDA-MB-231 cells and prostate cancer DU145 cells. Bex induced apoptotic cell death in MDA-MB-231 and DU145 cells. Furthermore, its effect resulted from an increased intracellular reactive oxygen species (ROS) level. Thus, the current study suggests that Bex may be useful for treating cancer, particularly breast and prostate cancer.

 Materials and methods <sec> <title>Cell culture and herbal extract

MDA-MB-231 and DU-145 cells (American Type Culture Collection, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and 1% penicillin-streptomycin (all Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Barley grass extract (Bex) was obtained from Chungbuk Agricultural Cooperation (Jecheon, South Korea). Bex was solubilized in water containing 0.01% dimethyl sulfoxide (DMSO). Therefore, all control groups in the experiment were treated with 0.01% DMSO.

 Cell viability assay

Cell viability was examined using an EZ-CYTOX cell viability/cytotoxicity assay kit (cat. no. EZ-000, Daeil Lab Service, Seoul, South Korea) according to the manufacturer's instructions. Briefly, 100,000 cells per well were cultured in 96-well plates and treated with different doses (0, 0.01, 0.1, 1, 10, 100, 250 and 500 µg/ml) of Bex for 72 h. Cell viability at 24, 48 and 72 h was measured using a microplate reader at a wavelength of 450 nm. Experiments were performed in triplicate and repeated three times independently.

 Apoptosis assay

Cells (3×106) were treated with different concentrations (0, 0.01, 0.1, 1, 10, 100, 250 and 500 µg/ml) of Bex for 24 h and stained with Annexin V-fluorescein isothiocyanate (FITC) and 7-aminoactinomycin D (7-AAD). Apoptotic cell death was determined using BD FACSCalibur flow cytometry with BD MultiSET software (BD Biosciences, San Jose, CA, USA). For western blot analysis, 1×106 cells were treated with 100 µg/ml Bex for 24 h and lysed with RIPA buffer. Protein (30 µg) was loaded onto SDS-PAGE and transferred to the membrane. After blocking with 5% milk, the membrane was incubated with an appropriate primary antibody for 1 h at room temperature. Anti-poly(ADP-ribose) polymerases (PARP) (cat. no. 9542), anti-cleaved caspase 8 (cat. no. 9496), anti-cleaved caspase 9 (cat. no. 7237), anti-cleaved caspase-3 (cat. no. 9664) and anti-β-tubulin (cat. no. 2146) antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA).

 Intracellular ROS detection assay

ROS levels were measured using 10 µM 2′,7′-dichlorofluorescin diacetate (H2DCF-DA; Molecular Probes; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Cells (1×106) were treated with 100 µg/ml Bex for 5 min and treated with H2DCF-DA for a further 24 h. The flow cytometry experiments were conducted in triplicate and repeated three times independently. Sigma-Aldrich N-acetyl-L-cystein (NAC; Merck KGaA, Darmstadt, Germany) at 10 mM was used to inhibit ROS induction. Cells (1×106) were pretreated with 10 mM NAC for 1 h before being treated with 100 µg/ml Bex for 24 h.

 Statistical analysis

All experiments were performed in triplicate and repeated three times independently. Statistical significance was evaluated using Student's t-test and analysis was conducted using SPSS version 24.0 software (IBM Corp., Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Bex inhibits cancer cell viability

To examine the effect of Bex on cancer cell viability, MDA-MB-231 breast cancer cells and DU-145 prostate cancer cells were treated with different concentrations (0, 0.01, 0.1, 1, 10, 100, 250 and 500 µg/ml) of Bex for 24, 48 and 72 h. Bex reduced the viability of those cancer cells in a dose-dependent manner (Fig. 1). Thus, the MTT assay data indicates that Bex inhibits cancer cell viability.

 Bex causes apoptosis of cancer cells

Annexin V assays were performed to examine whether Bex induces apoptosis of cancer cells. MDA-MB-231 or DU-145 cells were treated with 100 µg/ml Bex for 24 h, followed by Annexin V-FITC and 7-AAD. Flow cytometry data indicated that Bex induced apoptosis of the two types of cancer cell (Fig. 2A). Consistently, Bex induced PARP cleavage and caspase activation in the MDA-MB-231 cells (Fig. 2B; data for DU-145 not shown). Thus, the current data indicates that Bex causes apoptosis of cancer cells.

 Bex reduces the level of intracellular ROS

To examine whether Bex affects the production of intracellular ROS, MDA-MB-231 and DU-145 cells were treated with 100 µg/ml Bex for 1 h, and the intracellular ROS level was measured by detecting H2DCF-DA fluorescence using flow cytometry. Bex increased the intracellular ROS level in MDA-MB-231 breast and DU-145 prostate cancer cells (Fig. 3).

 Bex-mediated increase of intracellular ROS level is critical for apoptosis

Whether Bex-induced apoptosis required an increase of intracellular ROS level was subsequently examined. Bex-induced apoptosis was blocked in cells treated with NAC (Fig. 4). The data indicate that Bex-induced ROS accumulation is important for apoptosis.

 Discussion

Bex has long been incorporated into diets for disease prevention. However, to the best of our knowledge, its effects in cancer are yet to be investigated. In the present study, Bex caused apoptosis of breast and prostate cancer cells by increasing the intracellular ROS level. The present data indicate that cancer could be, in part, treated using natural products in food. Bex is widely used in food. Therefore, the present study demonstrates that foods containing Bex may be useful for cancer treatment during therapeutic interventions.

A recent study demonstrated that Bex induced apoptosis of leukemia and lymphoma cell lines (30). While not shown in the present study, the data demonstrated no apoptotic effect of Bex in Jurkat T cells (data not shown). It is possible that the experimental conditions, such as the extraction method and concentration, may have influenced the controversial results. In the present study, Bex induced apoptotic cell death of highly metastatic MDA-MB-231 breast cancer cells and DU-145 prostate cancer cells. Thus, the anti-cancer effect of Bex is not limited to blood cancer. This is consistent with results obtained using Bex-treated B16 melanoma cells or HepG2 hepatoma cells (31,32). Bex is one of the ingredients in cereal and the anti-cancer effect of peptides from cereal has previously been demonstrated (33). Furthermore, meta-analyses indicated that cereal reduces cancer risk (34,35). Thus, the present study provides evidence that dietary components are beneficial for cancer prevention and treatment.

In conclusion, Bex induction of ROS was crucial for apoptotic cell death. While the chemical components to produce ROS and induce apoptotic cell death in those breast and prostate cancer cells require further investigation, this is the first study, to the best of our knowledge, that shows the role of Bex in cancer cell death.

 Acknowledgements

The present study was supported by the Korean National University of Transportation 2016.

 References de MartelCFerlayJFranceschiSVignatJBrayFFormanDPlummerMGlobal burden of cancers attributable to infections in 2008: A review and synthetic analysisLancet Oncol13607615201210.1016/S1470-2045(12)70137-722575588 McGuireSWorld Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015Adv Nutr7418419201610.3945/an.116.01221126980827 HareJILammersTAshfordMBPuriSStormGBarrySTChallenges and strategies in anti-cancer nanomedicine development: An industry perspectiveAdv Drug Deliv Rev12538201710.1016/j.addr.2016.04.025 DawidczykCMKimCParkJHRussellLMLeeKHPomperMGSearsonPCState-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicinesJ Control Release187133144201410.1016/j.jconrel.2014.05.03624874289 BellouSPentheroudakisGMurphyCFotsisTAnti-angiogenesis in cancer therapy: Hercules and hydraCancer Lett338219228201310.1016/j.canlet.2013.05.01523707856 AliIWaniWASaleemKHaqueAPlatinum compounds: A hope for future cancer chemotherapyAnticancer Agents Med Chem13296306201310.2174/187152061131302001622583420 FauzeeNJTaxanes: Promising anti-cancer drugsAsian Pac J Cancer Prev12837851201121790213 Vera-BadilloFEAl-MubarakMTempletonAJAmirEBenefit and harms of new anti-cancer drugsCurr Oncol Rep15270275201310.1007/s11912-013-0303-y23435854 GhorbaniAClinical and experimental studies on polyherbal formulations for diabetes: Current status and future prospectiveJ Integr Med12336345201410.1016/S2095-4964(14)60031-525074883 JiangMYangJZhangCLiuBChanKCaoHLuAClinical studies with traditional Chinese medicine in the past decade and future research and developmentPlanta Med7620482064201010.1055/s-0030-125045620979016 IlyasUKatareDPAeriVNaseefPPA review on hepatoprotective and immunomodulatory herbal plantsPharmacogn Rev106670201610.4103/0973-7847.17654427041876 BahmaniMShirzadHShahinfardNSheivandiLRafieian-KopaeiMCancer phytotherapy: Recent views on the role of antioxidant and angiogenesis activitiesJ Evid Based Complementary Altern Med21565872156251572016 XuHZhaoXLiuXXuPZhangKLinXAntitumor effects of traditional Chinese medicine targeting the cellular apoptotic pathwayDrug Des Devel Ther927352744201526056434 IchikawaHNakamuraYKashiwadaYAggarwalBBAnticancer drugs designed by mother nature: Ancient drugs but modern targetsCurr Pharm Des1334003416200710.2174/13816120778236049218045194 PoonthananiwatkulBHowardRLWilliamsonEMLimRHCancer patients taking herbal medicines: A review of clinical purposes, associated factors, and perceptions of benefit or harmJ Ethnopharmacol1755866201510.1016/j.jep.2015.08.05226344852 LeeJWLeeWBKimWMinBILeeHChoSHTraditional herbal medicine for cancer pain: A systematic review and meta-analysisComplement Ther Med23265274201510.1016/j.ctim.2015.02.00325847565 LeggettSKoczwaraBMillerMThe impact of complementary and alternative medicines on cancer symptoms, treatment side effects, quality of life, and survival in women with breast cancer - a systematic reviewNutr Cancer67373391201510.1080/01635581.2015.100473125811312 BaoYKongXYangLLiuRShiZLiWHuaBHouWComplementary and alternative medicine for cancer pain: An overview of systematic reviewseCAM2014170396https://doi.org/10.1155/2014/17039624817897 WangCYBaiXYWangCHTraditional Chinese medicine: A treasured natural resource of anticancer drug research and developmentAm J Chin Med42543559201410.1142/S0192415X1450035924871650 OhnishiSTakedaHHerbal medicines for the treatment of cancer chemotherapy-induced side effectsFront Pharmacol614201510.3389/fphar.2015.0001425713534 ParkBJunJHJungJYouSLeeMSHerbal medicines for cancer cachexia: Protocol for a systematic reviewBMJ Open4e005016201410.1136/bmjopen-2014-00501624893603 LahouarLEl-BokSAchourLTherapeutic potential of young green barley leaves in prevention and treatment of chronic diseases: An overviewAm J Chin Med4313111329201510.1142/S0192415X1550074326477798 MiyazakiYTokunagaYTakagakiKTsusakiSTachibanaHYamadaKEffect of dietary cabbage fermentation extract and young barley leaf powder on immune function of Sprague-Dawley ratsJ Nutr Sci Vitaminol (Tokyo)47253257200110.3177/jnsv.47.25311575582 CremerLHeroldAAvramDSzegliGInhibitory capacity of some fractions isolated from a green barley extract upon TNF alpha production by the cells of the THP-1 human monocytes lineRoum Arch Microbiol Immunol5528529419969558963 CremerLHeroldAAvramDSzegliGA purified green barley extract with modulatory properties upon TNF alpha and ROS released by human specialised cells isolated from RA patientsRoum Arch Microbiol Immunol57231242199811845435 IguchiTKawataAWatanabeTMazumderTKTanabeSFermented barley extract suppresses the development of atopic dermatitis-like skin lesions in NC/Nga mice, probably by inhibiting inflammatory cytokinesBiosci Biotechnol Biochem73489493200910.1271/bbb.8043619270394 ChoiKCHwangJMBangSJSonYOKimBTKimDHLeeSAChaeMKimDHLeeJCMethanol extract of the aerial parts of barley (Hordeum vulgare) suppresses lipopolysaccharide-induced inflammatory responses in vitro and in vivoPharm Biol5110661076201310.3109/13880209.2013.76827423746221 HongHJai MaengWEffects of malted barley extract and banaba extract on blood glucose levels in genetically diabetic miceJ Med Food7487490200410.1089/jmf.2004.7.48715671695 YuYMChangWCChangCTHsiehCLTsaiCEEffects of young barley leaf extract and antioxidative vitamins on LDL oxidation and free radical scavenging activities in type 2 diabetesDiabetes Metab28107114200211976562 Robles-EscajedaELermaDNyakerigaAMRossJAKirkenRAAguileraRJVarela-RamirezASearching in mother nature for anti-cancer activity: Anti-proliferative and pro-apoptotic effect elicited by green barley on leukemia/lymphoma cellsPLoS One8e73508201310.1371/journal.pone.007350824039967 GhavamiLGoliaeiBTaghizadehBNikoofarAEffects of barley β-glucan on radiation damage in the human hepatoma cell line HepG2Mutat Res Genet Toxicol Environ Mutagen77516201410.1016/j.mrgentox.2014.09.00525435350 MengTXIrinoNKondoRMelanin biosynthesis inhibitory activity of a compound isolated from young green barley (Hordeum vulgare L.) in B16 melanoma cellsJ Nat Med69427431201510.1007/s11418-015-0902-z25827948 Ortiz-MartinezMWinklerRGarcía-LaraSPreventive and therapeutic potential of peptides from cereals against cancerJ Proteomics111165183201410.1016/j.jprot.2014.03.04424727098 LeiQZhengHBiJWangXJiangTGaoXTianFXuMWuCZhangLWhole grain intake reduces pancreatic cancer risk: A meta-analysis of observational studiesMedicine (Baltimore)95e2747201610.1097/MD.000000000000274726945361 AuneDKeumNGiovannucciEFadnesLTBoffettaPGreenwoodDCTonstadSVattenLJRiboliENoratTWhole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: Systematic review and dose-response meta-analysis of prospective studiesBMJ353i2716201610.1136/bmj.i271627301975

Bex reduces MDA-MB-231 and DU-145 cell viabilities. Cells were treated with different concentrations (0, 0.01, 0.1, 1, 10, 100, 250 and 500 µg/ml) of Bex for 72 h. Cell viabilities were measured at 24, 48 and 72 h. *P<0.05 vs. 0 µg/ml. Bex, barley grass extract.

Bex induces apoptotic cell death. (A) Cells were treated with 100 µg/ml Bex for 24 h and subjected to Annexin V-fluorescein isothiocyanate and 7-AAD staining. (B) MDA-MB-231 cells were treated with 100 µg/ml Bex for 24 h and subjected to western blot analysis. Bex, barley grass extract; 7-AAD, 7-aminoactinomycin D; Bax, BCL2 associated X, apoptosis regulator; Bcl-2, B-cell lymphoma 2; PARP, poly (ADP-ribose) polymerase.

Bex increases intracellular reactive oxygen species level. MDA-MB-231 and DU-145 cells were pretreated with 10 mM NAC for 1 h before being treated with 100 µg/ml Bex for 24 h. Bex, barley grass extract; NAC, N-acetyl-L-cystein.

Bex-induced apoptosis requires intracellular reactive oxygen species production. Cells were treated with Bex for 24 h with or without NAC, and then subjected to Annexin V-fluorescein isothiocyanate and 7-AAD staining. Bex, barley grass extract; NAC, N-acetyl-L-cystein; 7-AAD, 7-aminoactinomycin D.